Abstract: Disclosed herein is a method for manufacturing a population of human insulin producing cells from non-pancreatic ?-cells, wherein the resulting insulin producing cells have increased insulin content, or increased glucose regulated secretion of insulin, or a combination of both.
Type:
Grant
Filed:
April 1, 2020
Date of Patent:
April 4, 2023
Assignees:
ORGENESIS LTD., TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
Abstract: Disclosed herein are methods for manufacturing transdifferentiated populations of non-pancreatic human insulin producing cells, and methods for enriching populations of non-pancreatic ?-cells for cells comprising an enriched capacity for transcription factor-induced transdifferentiation into a pancreatic ?-cell phenotype and function.
Type:
Grant
Filed:
November 7, 2019
Date of Patent:
April 13, 2021
Assignees:
ORGENESIS LTD., TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
Abstract: The present invention provides methods for the sequential and temporally-regulated administration of pancreatic transcription factors to induce non-pancreatic cells to transdifferentiate and mature along the pancreatic ?-cell lineage. The present invention also provides methods for identifying, isolating and enriching transdifferentiation predisposed cells and methods for treating a degenerative pancreatic disorder such as diabetes.
Type:
Grant
Filed:
April 25, 2018
Date of Patent:
March 16, 2021
Assignees:
ORGENESIS LTD., TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
Abstract: Disclosed herein is a method for manufacturing a population of human insulin producing cells from non-pancreatic ?-cells, wherein the resulting insulin producing cells have increased insulin content, or increased glucose regulated secretion of insulin, or a combination of both.
Type:
Application
Filed:
April 1, 2020
Publication date:
September 24, 2020
Applicants:
ORGENESIS LTD., TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
Abstract: Disclosed herein is a method for manufacturing a population of human insulin producing cells from non-pancreatic ?-cells, wherein the resulting insulin producing cells have increased insulin content, or increased glucose regulated secretion of insulin, or a combination of both.
Type:
Grant
Filed:
November 29, 2018
Date of Patent:
June 2, 2020
Assignees:
ORGENESIS LTD., TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
Abstract: Disclosed herein are methods for manufacturing transdifferentiated populations of non-pancreatic human insulin producing cells, and methods for enriching populations of non-pancreatic ?-cells for cells comprising an enriched capacity for transcription factor-induced transdifferentiation into a pancreatic ?-cell phenotype and function.
Type:
Application
Filed:
November 7, 2019
Publication date:
May 7, 2020
Applicants:
ORGENESIS LTD., TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
Abstract: Disclosed is a three-dimensional (3D) cell cluster comprising transdifferentiated adult mammalian non-pancreatic beta cells having a mature pancreatic beta cell phenotype and function and a scaffold, wherein said transdifferentiated cells have an enhanced mature pancreatic beta cell phenotype compared to a 3D cell cluster without a scaffold and to similarly transdifferentiated cells cultured as a two-dimensional (2D) monolayer.
Type:
Application
Filed:
May 27, 2018
Publication date:
April 9, 2020
Applicants:
ORGENESIS LTD., TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
Abstract: Disclosed herein is a method for manufacturing a population of human insulin producing cells from non-pancreatic ?-cells, wherein the resulting insulin producing cells have increased insulin content, or increased glucose regulated secretion of insulin, or a combination of both.
Type:
Application
Filed:
November 29, 2018
Publication date:
May 9, 2019
Applicants:
ORGENESIS LTD., TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
Abstract: Disclosed herein is a method for manufacturing a population of human insulin producing cells from non-pancreatic ?-cells, wherein the resulting insulin producing cells have increased insulin content, or increased glucose regulated secretion of insulin, or a combination of both.
Type:
Grant
Filed:
December 30, 2015
Date of Patent:
January 15, 2019
Assignees:
ORGENESIS LTD., TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
Abstract: The present invention provides methods for the sequential and temporally-regulated administration of pancreatic transcription factors to induce non-pancreatic cells to transdifferentiate and mature along the pancreatic ?-cell lineage. The present invention also provides methods for identifying, isolating and enriching transdifferentiation predisposed cells and methods for treating a degenerative pancreatic disorder such as diabetes.
Type:
Application
Filed:
April 25, 2018
Publication date:
November 29, 2018
Applicants:
ORGENESIS LTD., TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
Abstract: The present invention provides methods for the sequential and temporally-regulated administration of pancreatic transcription factors to induce non-pancreatic cells to transdifferentiate and mature along the pancreatic ?-cell lineage. The present invention also provides methods for identifying, isolating and enriching transdifferentiation predisposed cells and methods for treating a degenerative pancreatic disorder such as diabetes.
Type:
Grant
Filed:
June 13, 2014
Date of Patent:
May 29, 2018
Assignees:
ORGENESIS LTD., TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.